In addition, HMGB1/TLR4, a therapeutic target for severe pneumonia, including COVID‐19, mediates the release of proinflammatory cytokines, and acetylcholine, heparin, statins, glycopyrrolate, ketamine, and resveratrol are important drug candidates as TLR4 inhibitors.243. The gene discussed is TLR4; the disease is COVID-19.